Eversept Partners, LP Viking Therapeutics, Inc. Transaction History

Eversept Partners, LP

  • $991 Million
  • Q4 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$47.39 - $80.2 $5.48 Million - $9.28 Million
115,671 Added 506.93%
138,489 $7.34 Million
Q1 2024

May 15, 2024
BUY
$17.4 - $94.5 $397,033 - $2.16 Million
22,818 New
22,818 $1.87 Million
Q4 2018

Feb 13, 2019
SELL
$7.16 - $16.21 $179,000 - $405,250
-25,000 Closed
0 $0
Q3 2018

Nov 08, 2023
BUY
$9.7 - $19.65 $242,499 - $491,249
25,000 New
25,000 $435,000
Q3 2018

Nov 14, 2018
BUY
$9.7 - $19.65 $242,499 - $491,249
25,000 New
25,000 $436,000

Others Institutions Holding VKTX

# of Institutions
471
Shares Held
66.4M
Call Options Held
5.88M
Put Options Held
3.83M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $2.34B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email